fcr

Rituximab is an anti-CD20 chimeric monoclonal antibody used to study certain autoimmune diseases and cancers.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is an IgG1 antibody inhibitor derived from mice, specifically targeting rat FcRn heavy chain heterodimers.

Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is a mouse-derived antibody, specifically targeting the FcRn heavy chain heterodimers. The isotype control for Anti-RatFcRnheavy chain heterodimers Antibody (1G3) is designated as MouseIgG1kappa, Isotype Control.

Anti-FcRH5 Antibody (MFRF3266A, DFRF4539A Naked Antibody) is a highly specific monoclonal antibody targeting FcRH5 (also known as IRTA2 or CD307e) and serves as the antibody backbone for the ADC DFRF4539A (RG-7598), which is used in research related to relapsed or refractory multiple myeloma.

Ofatumumab is a humanized monoclonal antibody targeting CD20. Ofatumumab acts on CD20-expressing B lymphocytes, inducing antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

CDX-1140 is a human IgG2 CD40 agonist antibody. It activates dendritic (DC) and B cells and induces NF-kB stimulation in CD40-expressing reporter cell lines. CDX-1140 functions independently of Fc receptor binding and works synergistically with natural CD40L signaling. It exhibits both direct and immune-mediated antitumor activity, making it useful for lymphoma and solid tumor research.